Skip to main content
SpringerLink
Log in

Growth Hormone Therapy and its Relationship to Insulin Resistance, Glucose Intolerance and Diabetes Mellitus

A Review of Recent Evidence

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

It is widely recommended that consideration should be given to the therapeutic use of growth hormone (GH) in adults with GH deficiency, whether the condition is of childhood or adult onset. One reason for this recommendation is the possibility that such treatment may reduce the excess cardiovascular risk which is associated with hypopituitarism. This excess risk has been well documented, with mortality ratios of 1.7 to 2.2 being quoted in different studies, and may be a result of the insulin resistance which occurs in hypopituitarism. However, it has also been suggested that this insulin resistance may itself be the result of GH deficiency, especially as GH deficiency is accompanied by suggestive morphological features such as central adiposity. There is, however, no direct evidence that the increase in cardiovascular risk in hypopituitarism is the result of GH deficiency, and the only prospective study designed to examine the relationship failed to find a statistically significant correlation between the two. Since GH administration may also have an independent adverse effect on insulin sensitivity and could thus cause a theoretical worsening of cardiovascular risk, it is important to review the observed effects of GH administration on carbohydrate metabolism in practice.

Interpretation of the literature is made difficult by many confounding factors, including differences in study duration, biochemical tools adopted, the use of selected populations and the dose-dependent effect of GH on synthesis of insulin-like growth factor-1. One of the most sensitive markers of a deterioration in insulin sensitivity is the serum insulin level. A rise in serum insulin (fasting, or post-glucose load) was reported in all studies in which it was measured. The majority of studies have also reported a rise in fasting blood glucose. A smaller proportion of reports noted an associated increase in postprandial glucose and in glycosylated haemoglobin (HbA1c) while a few reported new cases of either impaired glucose tolerance or frank diabetes mellitus. In general, however, the observed deterioration in insulin sensitivity was small and increases which occurred in blood glucose were small. Nevertheless, these data indicate that rather than lead to an improvement in insulin resistance in hypopituitarism, GH treatment may actually make it worse. As it is also known that even minor reductions in insulin sensitivity may be associated with a clinically significant increase in cardiovascular risk, further large-scale controlled trials are required before the efficacy and safety of GH treatment of adults can be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987; 8: 115–31

    Article  PubMed  CAS  Google Scholar 

  2. Press M. Growth hormone and metabolism. Diabetes Metab Rev 1998; 4: 391–414

    Article  Google Scholar 

  3. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901–3

    Article  PubMed  CAS  Google Scholar 

  4. Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the national cooperative growth study experience. J Clin Endocrinol Metab 1996; 81: 1704–10

    Article  PubMed  CAS  Google Scholar 

  5. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355: 610–3

    Article  PubMed  CAS  Google Scholar 

  6. Taskinen M, Saarinen-Pihkala UM, Hovi L, et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation. Lancet 2000; 356: 993–7

    Article  PubMed  CAS  Google Scholar 

  7. Reaven GM. The role of insulin in human disease. Diabetes 1998; 37: 1595–607

    Article  Google Scholar 

  8. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713–8

    Article  PubMed  CAS  Google Scholar 

  9. DECODE Study. Consequences of the new diagnostic criteria for diabetes in older men and women. Diabetes Care 1999; 22: 1667–71

    Google Scholar 

  10. Saydah SH, Eberhardt MS, Loria CM, et al. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001; 24: 447–53

    Article  PubMed  CAS  Google Scholar 

  11. DECODE Study. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617–21

    Google Scholar 

  12. Khaw K-T, Wareham N, Luben R, et al. Glycosylated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 15–8

    Article  PubMed  CAS  Google Scholar 

  13. Barrett-Connor E, Wingard DL. ‘Normal’ blood glucose and coronary risk. BMJ 2001; 322: 5–6

    Article  PubMed  CAS  Google Scholar 

  14. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477–90

    Article  PubMed  CAS  Google Scholar 

  15. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19: 491–503

    Article  PubMed  CAS  Google Scholar 

  16. Hew FL, O’Neal D, Kamarudin N, et al. Growth hormone deficiency and cardiovascular risk. Baillieres Clin Endocrinol Metab 1998; 12: 199–216

    Article  PubMed  CAS  Google Scholar 

  17. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 1999; 50: 1–15

    Article  CAS  Google Scholar 

  18. Carroll PV, Christ ER, Bengtsson BÅ, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 3: 382–95

    Article  Google Scholar 

  19. Buchanan CR, Preece MA, Milner RD. Mortality, neoplasia and Creutzfeld-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. BMJ 1991; 302: 824–8

    Article  PubMed  CAS  Google Scholar 

  20. Taback SP, Dean HJ. Mortality in Canadian children with growth hormone deficiency receiving growth hormone therapy 1967-1985. J Clin Endocrinol Metab 1996; 81: 693–6

    Article  Google Scholar 

  21. Hintz RL. Eternal vigilance -mortality in children with growth hormone deficiency. J Clin Endocrinol Metab 1996; 81: 1691–2

    Article  PubMed  CAS  Google Scholar 

  22. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8

    Article  PubMed  CAS  Google Scholar 

  23. Bates AS, Van’t Hoff W, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169–72

    Article  PubMed  CAS  Google Scholar 

  24. Bates AS, Bullivant B, Sheppard MC, et al. Life expectancy following surgery for pituitary tumours. Clin Endocrinol (Oxf) 1999; 50: 315–9

    Article  CAS  Google Scholar 

  25. Bulow B, Hagmart L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997; 46: 75–81

    Article  CAS  Google Scholar 

  26. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. Lancet 2001; 357: 425–31

    Article  PubMed  CAS  Google Scholar 

  27. Cuneo RC, Salomon F, MacGauley GA, et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 1992; 37: 1519–23

    Article  Google Scholar 

  28. Lehmann ED, Hopkins KD, Weissberger AJ, et al. Aortic distensibility in growth hormone deficient adults. Lancet 1993; 341: 309

    Article  PubMed  CAS  Google Scholar 

  29. Weaver JU, Thaventhiran L, Noonan K, et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 1994; 41: 639–48

    Article  CAS  Google Scholar 

  30. Mauras N, O’Brien KO, Welch S, et al. Insulin-like growth factor 1 and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid and calcium metabolism. J Clin Endocrinol Metab 2000; 85: 1686–94

    Article  PubMed  CAS  Google Scholar 

  31. Mauras N, Martinez V, Rini A, et al. Recombinant human insulin-like growth factor 1 has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose and lipid metabolism. J Clin Endocrinol Metab 2000; 85: 3036–42

    Article  PubMed  CAS  Google Scholar 

  32. Muller AF, Janssen JA, Hofland LJ, et al. Blockade of the growth hormone (GH) receptor unmasks GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab 2001; 86: 590–3

    Article  PubMed  CAS  Google Scholar 

  33. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth-hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997; 82: 82–8

    Article  PubMed  CAS  Google Scholar 

  34. Vance ML, Mauras N. Growth hormone therapy in adults and children. N Engl J Med 1999; 341: 1206–16

    Article  PubMed  CAS  Google Scholar 

  35. Drake WM, Coyte D, Camacho-Hubner C, et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998; 83: 3913–9

    Article  PubMed  CAS  Google Scholar 

  36. Murray RD, Skillicorn CJ, Howell SJ, et al. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clin Endocrinol (Oxf) 1999; 50: 749–57

    Article  CAS  Google Scholar 

  37. Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80: 153–9

    Article  PubMed  CAS  Google Scholar 

  38. Beshyah SA, Henderson A, Niththyananthan R, et al. The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995; 80: 356–63

    Article  PubMed  CAS  Google Scholar 

  39. Al-Shoumer KAS, Gray R, Anyaoku V, et al. Effects of four years’ treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. J Clin Endocrinol Metab 1998; 48: 795–802

    CAS  Google Scholar 

  40. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000; 85: 3762–9

    Article  PubMed  CAS  Google Scholar 

  41. Christopher M, Hew FL, Oakley M, et al. Defects in insulin action and skeletal muscle metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J Clin Endocrinol Metab 1998; 83: 1668–81

    Article  PubMed  CAS  Google Scholar 

  42. Christ ER, Cummings MH, Lumb PJ, et al. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin Endocrinol 1999; 81: 173–9

    Article  Google Scholar 

  43. Jorgensen JO, Rosenfalck AM, Fisker S, et al. Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study. Eur J Endocrinol 2000; 143: 593–9

    Article  PubMed  CAS  Google Scholar 

  44. Rosenfalck AM, Maghsoudi S, Fisker S, et al. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000; 85: 4172–81

    Article  Google Scholar 

  45. Seminara S, Merello G, Masi S, et al. Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Clin Endocrinol (Oxf) 1998; 49: 125–30

    Article  CAS  Google Scholar 

  46. Saenger P, Attie KM, Dimartino-Nardi J, et al. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. J Clin Endocrinol Metab 1998; 83: 3115–20

    Article  PubMed  CAS  Google Scholar 

  47. Lesage C, Walker J, Landier F, et al. Near normalisation of adolescent height with growth hormone therapy in very short children without growth hormone deficiency. J Pediatr 1991; 119: 29–34

    Article  PubMed  CAS  Google Scholar 

  48. Johansson G, Albertsso-Wikland K, Bengtsson B-A. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. J Clin Endocrinol Metab 1999; 84: 4516–24

    Article  Google Scholar 

  49. Norrelund H, Vahl N, Juul A, et al. Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 2000; 85: 1912–7

    Article  PubMed  CAS  Google Scholar 

  50. Ter Maaten JC, De Boer H, Kamp O, et al. Long-term effects of growth hormone replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999; 84: 2373–80

    Article  PubMed  CAS  Google Scholar 

  51. Florakis D, Hung V, Kaltas G, et al. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) 2000; 53: 453–9

    Article  CAS  Google Scholar 

  52. Cuneo RC, Judd S, Wallace JD, et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998; 83: 107–16

    Article  PubMed  CAS  Google Scholar 

  53. Abs R, Begtsson B-A, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999; 50: 703–13

    Article  CAS  Google Scholar 

  54. Bengtsson B-A, Abs R, Bennmarker H, et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 3929–35

    Article  PubMed  CAS  Google Scholar 

  55. Monson JP, Abs R, Bengtsson B-A, et al. Growth hormone deficiency and replacement in elderly hypopituitary adults. Clin Endocrinol (Oxf) 2000; 53: 281–9

    Article  CAS  Google Scholar 

  56. Chipman JJ, Attanasio AF, Birkett MA, et al. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997; 46: 473–81

    Article  CAS  Google Scholar 

  57. Hwu C-M, Kwok CF, Lai T-Y, et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997; 82: 3285–92

    Article  PubMed  CAS  Google Scholar 

  58. Vahl N, Juul A, Jorgensen JO, et al. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo controlled study. J Clin Endocrinol Metab 2000; 85: 1874–81

    Article  PubMed  CAS  Google Scholar 

  59. Davies JS, Obouobie K, Rees DA, et al. A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners. Clin Endocrinol (Oxf) 2000; 52: 295–303

    Article  CAS  Google Scholar 

  60. Fernholm R, Bramnert M, Hagg E, et al. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000; 85: 4104–12

    Article  PubMed  CAS  Google Scholar 

  61. Jeffcoate W. Can growth hormone therapy cause diabetes? Lancet 2000; 355: 589–90

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author has no conflicts of interest that are directly relevant to the contents of this article and received no funding for its preparation.

Author information

Authors and Affiliations

  1. Department of Diabetes and Endocrinology, City Hospital, Nottingham, NG5 1PB, England

    William Jeffcoate

Authors
  1. William Jeffcoate
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William Jeffcoate.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeffcoate, W. Growth Hormone Therapy and its Relationship to Insulin Resistance, Glucose Intolerance and Diabetes Mellitus. Drug-Safety 25, 199–212 (2002). https://doi.org/10.2165/00002018-200225030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225030-00005

Keywords

Search

Navigation